MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...

particularly when the disease takes a severe, chronic course. The typical skin change (primary lesion) of psoriasis is a sharply demarcated erythrosquamous plaque; it appears infiltrated and ...

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable ...

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

"The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are ... extending its use into other chronic inflammatory diseases like ...

VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for ...

our pivotal Phase 3 trial of ZORYVE foam in scalp and body plaque psoriasis. We enrolled patients with at least moderate ...

Armpit rashes can be caused by allergic reactions, infections, and chronic conditions ... like behind your knees and elbows. Unlike plaque psoriasis, the red rash from inverse psoriasis is usually ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...